{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:50:11Z","timestamp":1684471811089},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T00:00:00Z","timestamp":1417046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/hr.2014.166","type":"journal-article","created":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T06:55:40Z","timestamp":1417071340000},"page":"104-105","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and clinical outcome in combination therapy for high-risk elderly hypertensive patients"],"prefix":"10.1038","volume":"38","author":[{"given":"Seiji","family":"Umemoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,27]]},"reference":[{"key":"BFhr2014166_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S . Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014. Hypertens Res 2014; 37: 253\u2013387.","journal-title":"Hypertens Res"},{"key":"BFhr2014166_CR2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE . Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.","journal-title":"BMJ"},{"key":"BFhr2014166_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ . Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11\u2009000 participants from 42 trials. Am J Med 2009; 122: 290\u2013300.","journal-title":"Am J Med"},{"key":"BFhr2014166_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/hr.2012.216","volume":"36","author":"T Kohro","year":"2013","unstructured":"Kohro T, Yamazaki T, Sato H, Ohe K, Nagai R . The impact of a change in hypertension management guidelines on diuretic use in Japan: trends in antihypertensive drug prescriptions from 2005 to 2011. Hypertens Res 2013; 36: 559\u2013563.","journal-title":"Hypertens Res"},{"key":"BFhr2014166_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/hr.2014.141","volume":"38","author":"T Saruta","year":"2015","unstructured":"Saruta T, Ogihara T, Saito I, Rakugi H, Shimamoto K, Matsuoka H, Teramukai S, Higaki J, Ito S, Shimada K for the COLM Investigators. Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM study): safety and tolerability. Hypertens Res 2015; 38: 132\u2013136.","journal-title":"Hypertens Res"},{"key":"BFhr2014166_CR6","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ . ACCOMPLISH Trial Investigators.. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417\u20132428.","journal-title":"N Engl J Med"},{"key":"BFhr2014166_CR7","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","volume":"32","author":"T Ogihara","year":"2014","unstructured":"Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Shimada K, Ito S, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Kimura G, Umemura S, Ura N, Hayashi K, Odawara M, Tanahashi N, Ishimitsu T, Kashihara N, Morita S, Teramukai S . COLM Investigators.. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial1. J Hypertens 2014; 32: 2054\u20132063.","journal-title":"J Hypertens"},{"key":"BFhr2014166_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.amjmed.2011.12.010","volume":"125","author":"H Ogawa","year":"2012","unstructured":"Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR Study Group. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med 2012; 125: 981\u2013990.","journal-title":"Am J Med"},{"key":"BFhr2014166_CR9","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","volume":"29","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T . Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group.. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29: 1649\u20131659.","journal-title":"J Hypertens"},{"key":"BFhr2014166_CR10","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1253\/circj.CJ-13-0786","volume":"77","author":"J Hata","year":"2013","unstructured":"Hata J, Kiyohara Y . Epidemiology of stroke and coronary artery disease in Asia. Circ J 2013; 77: 1923\u20131932.","journal-title":"Circ J"},{"key":"BFhr2014166_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1291\/hypres.26.521","volume":"26","author":"T Katsuya","year":"2003","unstructured":"Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T . Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res 2003; 26: 521\u2013525.","journal-title":"Hypertens Res"},{"key":"BFhr2014166_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/hr.2011.216","volume":"35","author":"T Ogihara","year":"2012","unstructured":"Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T . Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE Trial. Hypertens Res 2012; 35: 441\u2013448.","journal-title":"Hypertens Res"},{"key":"BFhr2014166_CR13","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(05)67760-4","volume":"366","author":"BB Granger","year":"2005","unstructured":"Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA . CHARM investigators.. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366: 2005\u20132011.","journal-title":"Lancet"},{"key":"BFhr2014166_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/hr.2013.85","volume":"36","author":"S Shin","year":"2013","unstructured":"Shin S, Song H, Oh SK, Choi KE, Kim H, Jang S . Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res 2013; 36: 1000\u20131005.","journal-title":"Hypertens Res"},{"key":"BFhr2014166_CR15","doi-asserted-by":"publisher","first-page":"e75027","DOI":"10.1371\/journal.pone.0075027","volume":"8","author":"N Takabayashi","year":"2013","unstructured":"Takabayashi N, Urushihara H, Kawakami K . Biased safety reporting in blinded randomized clinical trials: meta-analysis of angiotensin receptor blocker trials. PLoS One 2013; 8: e75027.","journal-title":"PLoS One"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2014166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2014166","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2014166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:13:59Z","timestamp":1684430039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2014166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,27]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFhr2014166"],"URL":"https:\/\/doi.org\/10.1038\/hr.2014.166","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,27]]},"assertion":[{"value":"27 November 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SU received consultant fee from Boehringer Ingelheim Japan, honoraria from Kyowa Hakko Kirin, Takeda Pharmaceutical, Mochida Pharmaceutical, Eisai and Asuka Pharmaceutical and grant from Maruha Nichiro Holdings.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}